ACTU

ACTU

USD

Actuate Therapeutics Inc. Common stock

$6.590+0.090 (1.385%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$6.500

Máximo

$6.660

Mínimo

$6.461

Volume

0.02M

Fundamentos da empresa

Capitalização de mercado

153.2M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.07M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $5.47Atual $6.590Máximo $11.99

Notícias relacionadas

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.

Ver mais
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through

Ver mais
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
GlobeNewswire

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Ver mais
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
GlobeNewswire

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Ver mais
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Ver mais
Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.